GB201215527D0 - Compounds for the treatment of muscular dystrophy - Google Patents

Compounds for the treatment of muscular dystrophy

Info

Publication number
GB201215527D0
GB201215527D0 GBGB1215527.1A GB201215527A GB201215527D0 GB 201215527 D0 GB201215527 D0 GB 201215527D0 GB 201215527 A GB201215527 A GB 201215527A GB 201215527 D0 GB201215527 D0 GB 201215527D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treatment
muscular dystrophy
dystrophy
muscular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1215527.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GBGB1215527.1A priority Critical patent/GB201215527D0/en
Publication of GB201215527D0 publication Critical patent/GB201215527D0/en
Ceased legal-status Critical Current

Links

GBGB1215527.1A 2012-08-31 2012-08-31 Compounds for the treatment of muscular dystrophy Ceased GB201215527D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1215527.1A GB201215527D0 (en) 2012-08-31 2012-08-31 Compounds for the treatment of muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1215527.1A GB201215527D0 (en) 2012-08-31 2012-08-31 Compounds for the treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
GB201215527D0 true GB201215527D0 (en) 2012-10-17

Family

ID=47075048

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1215527.1A Ceased GB201215527D0 (en) 2012-08-31 2012-08-31 Compounds for the treatment of muscular dystrophy

Country Status (1)

Country Link
GB (1) GB201215527D0 (en)

Similar Documents

Publication Publication Date Title
IL237275A0 (en) Compounds for the treatment of paramoxyvirus viral infectiones
HK1209456A1 (en) Oligonucleotide for the treatment of muscular dystrophy patients
HK1197400A1 (en) Compounds for the treatment of hiv hiv
PL2892525T3 (en) Methods of treating muscular dystrophy
HK1206338A1 (en) Pyrimidine compounds for the treatment of cancer
EP2925752A4 (en) Pyrimidine compounds for the treatment of cancer
EP2807111A4 (en) Multifunctional nanomaterials for the treatment of cancer
HK1204605A1 (en) Functionalized thieno-indole derivatives for the treatment of cancer
IL236450A0 (en) Process for the preparation of 5-fluoro-1h-pyrazoles
PL399419A1 (en) Process for the preparation of 4-methoxydihydrochalcone
PL399418A1 (en) Process for the preparation of 4-methoxydihydrochalcone
IL233938A (en) Process for the preparation of substituted phenylpropanones
SI2846774T1 (en) Pharmaceutical composition for the treatment of duchenne muscular dystrophy
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
GB201215527D0 (en) Compounds for the treatment of muscular dystrophy
IL236873A0 (en) Therapeutic compounds
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
GB201210184D0 (en) Formulations of metronidazole for the treatment of pouchitis
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
HUP1200675A2 (en) Process for the preparation of pyrimidinyl-piperazines
GB201119533D0 (en) Compounds for the treatment of neoplasia
GB201212604D0 (en) New treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)